Jazz Pharmaceuticals appoints vice president of r&d

Jeffrey Tobias also takes chief medical officer role

Jazz Pharmaceuticals, a US developer of pharmaceuticals for neurology and psychiatry based in Palo Alto, California, has appointed Jeffrey Tobias, as senior vice president of research and development and chief medical officer. He takes up his new roles on 17 October.

Tobias has 20 years of experience in the biopharmaceutical industry across all phases of drug development, including regulatory filings in the US and Europe.

He has broad experience with a variety of therapeutic products spanning numerous clinical areas, including pain and neurological disorders.

Most recently, he was executive vice president of research and development at NeurogesX, where he has also been chief medical officer since 2005.

Prior to this Tobias was managing director of an independent biopharmaceutical consulting firm from 1996 to 2006, where he supported clients in all aspects of clinical development, technology assessment and strategic planning. He has also served in various roles in drug discovery and clinical development at ALZA, Chiron and XOMA.

Tobias also has 10 years of experience in clinical and academic medicine, focusing on internal and pulmonary and critical care medicine.

You may also like

Pharmaceutical

Jazz Pharmaceuticals commercialises enhanced antibody, Ziihera, for biliary tract cancer

The therapeutic antibody was developed using ProBioGen's GlyMaxX technology, creating an afucosylated product with more ADCC-mediated cell killing activity
Design & Build

Jazz Pharmaceuticals among ISPE FOYA winners

Ardmac supplied and installed the cleanroom in the biopharmaceutical company's winning facility in Ireland
Finance

Jazz concludes merger with Azur Pharma

Forms a specialist in CNS and women’s health products
Regulatory

WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants

The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Regulatory

FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection

The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
Manufacturing

Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market

Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
Subscribe now